<SEC-DOCUMENT>0001104659-25-033481.txt : 20250410
<SEC-HEADER>0001104659-25-033481.hdr.sgml : 20250410
<ACCEPTANCE-DATETIME>20250410060023
ACCESSION NUMBER:		0001104659-25-033481
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250410
DATE AS OF CHANGE:		20250410

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CONDUIT PHARMACEUTICALS INC.
		CENTRAL INDEX KEY:			0001896212
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				873272543
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-93313
		FILM NUMBER:		25826353

	BUSINESS ADDRESS:	
		STREET 1:		4851 TAMIAMI TRAIL NORTH
		STREET 2:		SUITE 200
		CITY:			NAPLES
		STATE:			FL
		ZIP:			34103
		BUSINESS PHONE:		(646) 491 9132

	MAIL ADDRESS:	
		STREET 1:		4851 TAMIAMI TRAIL NORTH
		STREET 2:		SUITE 200
		CITY:			NAPLES
		STATE:			FL
		ZIP:			34103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Murphy Canyon Acquisition Corp.
		DATE OF NAME CHANGE:	20211130

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ASTRAZENECA PLC
		CENTRAL INDEX KEY:			0000901832
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		1 FRANCIS CRICK AVENUE
		STREET 2:		CAMBRIDGE BIOMEDICAL CAMPUS
		CITY:			CAMBRIDGE
		STATE:			X0
		ZIP:			CB2 0AA
		BUSINESS PHONE:		011 44 20 7304 5000

	MAIL ADDRESS:	
		STREET 1:		1 FRANCIS CRICK AVENUE
		STREET 2:		CAMBRIDGE BIOMEDICAL CAMPUS
		CITY:			CAMBRIDGE
		STATE:			X0
		ZIP:			CB2 0AA

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZENECA GROUP PLC
		DATE OF NAME CHANGE:	19930422
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <previousAccessionNumber>0001104659-24-107836</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: ASTRAZENECA PLC -->
          <cik>0000901832</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>1</amendmentNo>
      <securitiesClassTitle>Common Stock, par value $0.0001 per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>03/31/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001896212</issuerCik>
        <issuerName>Conduit Pharmaceuticals Inc.</issuerName>
        <issuerCusip>20678X106</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>4851 Tamiami Trail North</com:street1>
          <com:street2>Suite 200</com:street2>
          <com:city>Naples</com:city>
          <com:stateOrCountry>FL</com:stateOrCountry>
          <com:zipCode>34103</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>AstraZeneca PLC</reportingPersonName>
      <memberGroup>b</memberGroup>
      <citizenshipOrOrganization>X0</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>73892.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>73892.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>73892.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>1.1</classPercent>
      <typeOfReportingPerson>CO</typeOfReportingPerson>
      <comments>1 Represents shares directly held by AstraZeneca AB, a wholly-owned subsidiary of AstraZeneca PLC. AstraZeneca PLC and AstraZeneca AB may each be deemed to have sole voting and dispositive power over the shares.
2 See footnote 1.
3 See footnote 1.
4 The percentage ownership was calculated based on 6,662,755 shares of the issuer's common stock outstanding as of March 28, 2025, as reported in the issuer's Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 28, 2025.</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>AstraZeneca AB</reportingPersonName>
      <memberGroup>b</memberGroup>
      <citizenshipOrOrganization>V7</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>73892.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>73892.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>73892.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>1.1</classPercent>
      <typeOfReportingPerson>CO</typeOfReportingPerson>
      <comments>5 See footnote 1.
6 See footnote 1.
7 See footnote 1.
8 See footnote 4.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Conduit Pharmaceuticals Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>4851 Tamiami Trail North, Suite 200 Naples, FL, 34103</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>See response to 2(c)</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>See response to 2(c)</principalBusinessOfficeOrResidenceAddress>
        <citizenship>This statement is filed on behalf of:
AstraZeneca PLC
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
Citizenship: United Kingdom
AstraZeneca AB
SE-151 85 Sodertalje
Sweden
Citizenship: Sweden</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>73,892</amountBeneficiallyOwned>
        <classPercent>1.1%. The percentage stated herein is based on 6,662,755 shares of the issuer's common stock outstanding as of March 28, 2025, as reported in the issuer's Form 10-K filed with the SEC on March 28, 2025.</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>AstraZeneca PLC: 73,892 shares
AstraZeneca AB: 73,892 shares</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>AstraZeneca PLC: 0 shares
AstraZeneca AB: 0 shares</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>AstraZeneca PLC: 73,892 shares
AstraZeneca AB: 73,892 shares</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>AstraZeneca PLC: 0 shares
AstraZeneca AB: 0 shares</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>N</notApplicableFlag>
        <classOwnership5PercentOrLess>Y</classOwnership5PercentOrLess>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>AstraZeneca PLC</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Adrian Kemp</signature>
        <title>Adrian Kemp, Company Secretary</title>
        <date>04/10/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>AstraZeneca AB</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Lars-Johan Cederbrant</signature>
        <title>Lars-Johan Cederbrant, Director and CFO</title>
        <date>04/10/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
